Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592888 · ClinicalTrials.gov registry record · Phase 1
DC Vaccine in Pancreatic Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03592888: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT03592888 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592888, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.
Interventions
- DRUG mDC3/8-KRAS Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592888
The ClinicalTrials.gov registry entry for NCT03592888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mDC3/8-KRAS Vaccine is the first listed.
NCT03592888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03592888 about?
NCT03592888 is a clinical study titled "DC Vaccine in Pancreatic Cancer". This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.
What is the current status of trial NCT03592888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-11-20. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT03592888?
The interventions under investigation include: mDC3/8-KRAS Vaccine (DRUG).
Who is sponsoring clinical trial NCT03592888?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.